Back to Search
Start Over
Blinatumomab improves outcomes for pediatric patients with low-risk B-cell acute lymphoblastic leukemia in first marrow relapse.
- Source :
-
Translational pediatrics [Transl Pediatr] 2024 Mar 27; Vol. 13 (3), pp. 530-534. Date of Electronic Publication: 2024 Mar 06. - Publication Year :
- 2024
-
Abstract
- Competing Interests: Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tp.amegroups.com/article/view/10.21037/tp-23-521/coif). I.A. reports serving on Advisory Boards for Amgen and KiTE Pharm. I.A. served as a consultant for Amgen, and received consulting fees and payment from them. The other author has no conflicts of interest to declare.
Details
- Language :
- English
- ISSN :
- 2224-4344
- Volume :
- 13
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Translational pediatrics
- Publication Type :
- Editorial & Opinion
- Accession number :
- 38590377
- Full Text :
- https://doi.org/10.21037/tp-23-521